Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study
about
Cardiovascular-renal axis disorders in the domestic dog and cat: a veterinary consensus statementDifferentiating the aging of the mitral valve from human and canine myxomatous degenerationDiscrepancies in identification of left atrial enlargement using left atrial volume versus left atrial-to-aortic root ratio in dogs.Clinical severity score system in dogs with degenerative mitral valve diseaseA retrospective study of degenerative mitral valve disease in small-breed dogs: Survival and prognostic variables.Assessment of Lung Ultrasound B-Lines in Dogs with Different Stages of Chronic Valvular Heart Disease.Mitral Regurgitation Severity and Left Ventricular Systolic Dimension Predict Survival in Young Cavalier King Charles Spaniels.Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges.Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.Myxomatous mitral valve disease in dogs: does size matter?Longitudinal electrocardiographic evaluation of dogs with degenerative mitral valve diseaseUsefulness of conventional and tissue Doppler echocardiography to predict congestive heart failure in dogs with myxomatous mitral valve diseasePrevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve diseaseLong-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy.Comparison of the effects of long-term pimobendan and benazepril administration in normal cats.Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.Degenerative Valvular Disease in the Cavalier King Charles Spaniel: Results of the UK Breed Scheme 1991-2010.Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failureA review of the pharmacology and clinical uses of pimobendan.Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays.Cardiovascular effects of pimobendan in healthy mature horses.Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.Long-term outcome in dogs undergoing mitral valve repair with suture annuloplasty and chordae tendinae replacement.Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease.Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.Assessment of mitral regurgitation in dogs: comparison of results of echocardiography with magnetic resonance imaging.Safety of a benazepril and pimobendan combination tablet in adult healthy dogs.Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs.The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
P2860
Q26786569-35125C7E-4C76-41DF-A223-B9098FA0ED98Q27006882-1F052382-BEBF-405C-A5B1-3663F95F4159Q30381051-7BF7B8E2-2C03-4935-A351-6AE2E824D8A0Q33165468-685C4E59-F822-4A6D-821F-D4E19A10AED4Q33168106-B8992CBB-8A29-4DE7-AD6B-79F916A77BD0Q33698491-A3020B42-8EF8-4437-B799-F6B80A6333DDQ33900132-AD4B8D27-84FB-4411-95BA-B167D02F5426Q33900204-9B3E10AB-E49F-41AB-A1C2-84192E104EC3Q34252567-05E30C30-CF2F-427D-B836-14812F2D4BA1Q34636070-148D5338-9FEC-4814-AA38-DA734EF554FBQ36873262-AAA83A74-EC31-431C-A36F-D5999E0FE986Q36873723-7E4BCA49-4C6D-412C-9393-CDDC312BAC56Q36975190-E04058C6-8941-481E-BE9D-AFC1CBE96776Q37020283-E518CDB1-06AD-4FA0-A41F-E6079766C6C5Q37157199-EB039D95-A5F3-41E4-B017-A124677D14D0Q37422789-923796C5-42C7-4237-BF8B-8A562031996FQ37601883-DDB1B2BD-5F82-4638-B6B0-0332A50B02F7Q37621312-C97A36FA-652E-42D3-B0D9-2827B67594E4Q38038679-8BFD72CA-1CBC-437F-9A8B-8D8A89A38E2BQ38816520-96280317-8205-499C-BB32-56C94DD866D1Q41251260-A3A44791-4EAA-4072-B493-42222567F550Q43474089-DB7127FA-CB2D-41D8-B83B-40473F5F8A8FQ44953883-1789305E-EFFA-48BA-AF6E-911A8FC3CC8AQ44974418-F813044B-058F-4DF3-A796-3D1F2D65D20CQ45041217-8467A234-B84D-4605-9C80-DC33C804586AQ45070678-39BBFA61-0C76-4D3E-BB31-7DC4E74D7C7CQ45730573-90B7D653-9760-4146-BC13-AE1FE83ECAB1Q46092528-5D49A82C-A2B8-487B-8200-57131D063C59Q48118960-05EAFF4D-C1BB-4F14-8AA4-30279FEC2F43Q48224160-0D0B6F33-8614-494A-9752-E14AE720810BQ49529505-0F8B4947-12A2-47A0-A826-AE76739E19F9Q53496972-5DD3DCE2-AC21-43C8-8C8E-DFCD4E98F30AQ53500147-C2E2F281-D611-418A-934F-3234E4804FECQ58738210-492C4754-7D12-4F9B-AE89-40C2184DC49F
P2860
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@ast
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@en
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@nl
type
label
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@ast
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@en
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@nl
prefLabel
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@ast
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@en
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@nl
P2093
P50
P3181
P1476
Effect of pimobendan or benaze ...... valve disease: the QUEST study
@en
P2093
A Eriksson
A Kovacević
A V Eggertsdottir
B Gavaghan
C J L Little
P304
P3181
P356
10.1111/J.1939-1676.2008.0150.X
P407
P577
2008-07-11T00:00:00Z